Mucosal vaccine development for botulinum intoxication (Q36728788)

15 August 2017

1 reference

title

Mucosal vaccine development for botulinum intoxication (English)

1 reference

15 August 2017

0 references

Kohtaro Fujihashi

1

1 reference

15 August 2017

Herman F Staats

series ordinal

2

1 reference

15 August 2017

Shunji Kozaki

series ordinal

3

1 reference

15 August 2017

David W Pascual

series ordinal

4

1 reference

15 August 2017

1 February 2007

1 reference

Expert Review of Vaccines

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

1

1 reference

15 August 2017

35-45

1 reference

The role of nasopharyngeal lymphoid tissue

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Clostridium botulinum toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Molecular pharmacology of botulinum toxin and tetanus toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Botulinum toxin as a carrier for oral vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

The changing epidemiology of adult botulism in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

On the size of the toxic particle passing the intestinal barrier in botulism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Observations on the Type A toxin of Clostridium botulinum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Identifying the principal protective antigenic determinants of type A botulinum neurotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

B-1 cells and their reactivity with the murine intestinal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Intracellular neutralization of virus by immunoglobulin A antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Development of vaccines for prevention of botulism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Botulinum Toxin as a Biological Weapon: Medical and Public Health Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

The health hazards of formaldehyde

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Induction of acute lung injury after intranasal administration of toxin botulinum a complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F H(C) fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Bioterriorism: from threat to reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Clinical recognition and management of patients exposed to biological warfare agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Identification of the major steps in botulinum toxin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

Mucosal immunology of the upper respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.1.35

21 January 2018

Identifiers

DOI

10.1586/14760584.6.1.35

1 reference

15 August 2017

1 reference